{
  "docId": "019dd923-622c-750b-8b99-9ee2a1e788fb",
  "docSlug": "1233d0b05ad9",
  "documentTitle": "PROCEPT BioRobotics Corporation (PRCT)",
  "authorId": "54_Spruce_Point_Capital",
  "authorName": "Spruce Point Capital Management",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "short_seller",
  "sourceTypeLabel": "Short seller",
  "presentationDate": "2025-01-16 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.3333334,
  "pageNumber": 73,
  "pageCount": 100,
  "prevPage": 72,
  "nextPage": 74,
  "slideType": "cite_precedent",
  "function": "cite_precedent",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": "Includes a quote from a Spruce Point interview with a urologist to cast doubt on the target company's market positioning.",
  "elementsJson": [
    "paragraph",
    "callout_box",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b99-9ee2a1e788fb/73",
  "deckHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b99-9ee2a1e788fb#slide-73",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.96,
        "x": 0.02,
        "y": 0.305
      },
      "kind": "callout",
      "text": "Excerpts From “More Patients Opting for Close Monitoring of Early-stage Prostate Cancer”, Leapman, et al",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c108e76-d825-4cf3-a4b4-efee9f20df01",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "The number of men diagnosed with intermediate-risk prostate cancer opting for AS/WW more than doubled in 10 years, increasing from 5.0% in 2010 to 12.3% in 2020, showing a shift towards more conservative management.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-ee36-760b-929b-d2fce3dd61ff",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.78,
        "x": 0.2,
        "y": 0.56
      },
      "kind": "paragraph",
      "text": "The data revealed that more people were diagnosed with intermediate-risk prostate cancer over the years, and more of them were choosing AS/WW instead of going immediately into treatment, showing a shift towards more conservative management. The number of men diagnosed with intermediate-risk prostate cancer opting for AS/WW more than doubled in 10 years, increasing from 5.0% in 2010 to 12.3% in 2020, showing a shift towards more conservative management.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d183c05-1e59-47ce-8470-a70f1c2ff068",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.11,
        "w": 0.96,
        "x": 0.02,
        "y": 0.17
      },
      "kind": "paragraph",
      "text": "According to the American Cancer Society, surgery is a common choice to try to cure prostate cancer if it is not thought to have spread outside the prostate. However, recent research from the Yale School of Medicine found a “substantial increase” in the adoption of active surveillance and watchful waiting treatment strategies over the past decade. Thus, fewer patients are directly proceeding to a prostatectomy early in the treatment cycle.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad7a3b34-9305-4d2b-82f0-ea2c56fbe2c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.78,
        "x": 0.2,
        "y": 0.36
      },
      "kind": "quote",
      "text": "“One of the challenges in managing localized prostate cancer is determining the risk posed to an individual patient,” said the study's senior author Dr. Michael Leapman... “We know that many prostate cancers will not spread or cause symptoms if untreated. There have been major changes over the past decade with much more use of initial monitoring for cancers determined to be ‘low risk.’”",
      "attrs": null,
      "subkind": "pull-quote",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dfe24edc-ab07-4b4a-98de-5e04ac56ecd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.74,
        "x": 0.24,
        "y": 0.84
      },
      "kind": "quote",
      "text": "“I have a hard time kind of understanding exactly where they're going to position themselves in the world of prostate cancer.”",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "73e66fe3-da94-40c4-9d9c-e8f05805845a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "\"One of the challenges in managing localized prostate cancer is determining the risk posed to an individual patient,\" said the study's senior author Dr. Michael Leapman, the clinical program leader of the prostate and urologic cancers program at Yale Cancer Center and an associate professor of urology at Yale School of Medicine. \"We know that many prostate cancers will not spread or cause symptoms if untreated. There have been major changes over the past decade with much more use of initial monitoring for cancers determined to be 'low risk.' We wanted to determine whether conservative management, including active surveillance or watchful waiting, has also increased for cancers with 'intermediate risk' features as well.\" — Dr. Michael Leapman, Yale School of Medicine; \"I have a hard time kind of understanding exactly where they're going to position themselves in the world of prostate cancer.\" — Private Practice Urologist",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd952-ee36-760b-929b-d42877afbea3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.6,
        "x": 0.02,
        "y": 0.97
      },
      "kind": "source-note",
      "text": "Source: American Cancer Society, “More Patients Opting for Close Monitoring of Early-stage Prostate Cancer”, Leapman, et al",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "162d5c32-fe37-44b2-86f9-5b86f3c1a205",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.65,
        "x": 0.305,
        "y": 0.03
      },
      "kind": "title",
      "text": "Prostate Cancer Treatment Plans May Be Shifting Toward A More Conservative Approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b2d5692-e419-4df3-9dc3-14d4f72f7fc3",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "authority-citation",
      "slug": null,
      "matchId": "e6335c42-d24f-410b-a629-cfb50c294f3f",
      "evidence": "Citing Yale School of Medicine and American Cancer Society to support the thesis.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}